PA-824: Bicyclic Nitroimidazole Inhibitor for Drug-Resistant Tuberculosis Research

Executive Summary: PA-824 (CAS 187235-37-6) is a high-purity bicyclic nitroimidazole derivative with potent activity against both replicating and non-replicating Mycobacterium tuberculosis, including drug-resistant strains (Rahman et al., 2026). Its mechanism combines inhibition of ketomycolate biosynthesis and intracellular nitric oxide (NO) release (APExBIO). PA-824 demonstrates minimum inhibitory concentrations (MIC) between 0.015–0.25 μg/mL under standard in vitro conditions, with an IC50 less than 2.8 μM. The compound is insoluble in water and ethanol but dissolves at ≥17.85 mg/mL in DMSO, making it suitable for diverse laboratory workflows. These properties, combined with robust quality controls, position PA-824 as a leading research compound for tuberculosis drug development and resistance studies.

Biological Rationale

Tuberculosis (TB) remains a major global health challenge, exacerbated by the emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis. Conventional therapies are lengthy and frequently fail against persistent bacterial populations. Bicyclic nitroimidazoles, such as PA-824, represent a new class of anti-tuberculosis drugs with unique mechanisms addressing both active and latent TB infections (Rahman et al., 2026). These compounds are designed to kill both actively replicating and dormant bacilli by disrupting essential metabolic and cell wall biosynthesis pathways. PA-824 specifically inhibits ketomycolate biosynthesis, a critical step in mycolic acid production required for the integrity of the mycobacterial cell wall. Additionally, its activation within the bacterial cell leads to the release of nitric oxide, which interferes with bacterial respiration and energy production (PA-824 Mechanisms Article). This dual mechanism is especially effective against strains tolerant to conventional antibiotics.

Mechanism of Action of PA-824

PA-824 acts as a prodrug requiring enzymatic reduction within Mycobacterium tuberculosis. The activation process involves a deazaflavin-dependent nitroreductase, which catalyzes reductive activation of the nitroimidazole core, leading to the intracellular release of nitric oxide (NO) (Rahman et al., 2026). The NO generated disrupts the electron transport chain, particularly inhibiting the respiratory cytochrome oxidases (cytochrome bcc:aa3 and bd oxidase branches), causing energy depletion and cell death. Concurrently, PA-824 inhibits ketomycolate biosynthesis, blocking the formation of mycolic acids essential for cell wall construction. This dual-action mechanism accounts for PA-824’s bactericidal activity against both replicating and non-replicating bacterial cells. Unlike conventional antibiotics, PA-824’s intracellular activation and NO-mediated mechanisms make resistance less likely to develop rapidly (Workflow Integration Article), particularly when used in combination regimens.

Evidence & Benchmarks

• PA-824 achieves MIC values ranging from 0.015 to 0.25 μg/mL against M. tuberculosis in standard in vitro assays at 37°C in Middlebrook 7H9 medium (Rahman et al., 2026).
• IC50 values for PA-824 are reported below 2.8 μM under aerobic culture conditions (APExBIO).
• PA-824 demonstrates bactericidal activity against both replicating and non-replicating (hypoxic or nutrient-deprived) M. tuberculosis populations (Rahman et al., 2026).
• PA-824 remains effective against strains resistant to rifampicin and isoniazid, confirming activity against drug-resistant TB (Drug-Resistant TB Article).
• Solubility in DMSO is at least 17.85 mg/mL; compound is insoluble in water and ethanol (25°C) (APExBIO).
• Quality control for APExBIO PA-824 (A1736) includes COA, HPLC, NMR, and MSDS documentation, with ≥98% purity (APExBIO).

Applications, Limits & Misconceptions

PA-824 is primarily utilized in preclinical research to assess new anti-tuberculosis drug regimens, study resistance mechanisms, and benchmark novel compounds against drug-resistant M. tuberculosis. It is instrumental in MIC determination, synergy testing with agents like telacebec (Q203), and mechanistic studies of NO-mediated bacterial killing (Rahman et al., 2026). APExBIO supplies PA-824 for research use only; it is not approved for clinical or diagnostic applications.

Common Pitfalls or Misconceptions

• PA-824 is not soluble in water or ethanol; using inappropriate solvents leads to inaccurate dosing or precipitation.
• The compound is a research reagent only; it is not licensed for therapeutic or clinical use.
• Effectiveness is documented only for mycobacterial species; it does not exhibit broad-spectrum antibacterial activity.
• Storage above -20°C or repeated freeze-thaw cycles can degrade compound integrity.
• PA-824’s activity depends on activation by mycobacterial nitroreductases; its effect may not translate to non-mycobacterial pathogens.

Workflow Integration & Parameters

For laboratory application, PA-824 is prepared as a stock solution in DMSO (≥17.85 mg/mL), aliquoted, and stored at -20°C for maximal stability. Working solutions should be freshly prepared and used within 24 hours to prevent degradation. Standard MIC assays involve diluting PA-824 in Middlebrook 7H9 broth with OADC supplement, incubating with M. tuberculosis at 37°C for 7–14 days. Controls must include vehicle (DMSO) and reference compounds (e.g., rifampicin, isoniazid) for benchmarking. PA-824 is compatible with checkerboard assays for synergy studies and can be incorporated into triple-drug regimens for advanced resistance modeling (Workflow Integration Article), supporting combination studies with Q203 and ND-011992 (Rahman et al., 2026).

This article extends recent coverage in PA-824: Bicyclic Nitroimidazole for Drug-Resistant Tuberc... by detailing specific workflow protocols and highlighting new evidence on synergy with terminal oxidase inhibitors. For more on stepwise workflows and troubleshooting, see PA-824: Bicyclic Nitroimidazole for Advanced Tuberculosis..., which this article updates with the latest synergy and resistance suppression data. To understand advanced mechanisms, see PA-824: Next-Generation Bicyclic Nitroimidazole for Tuber...; this article clarifies PA-824's dual target inhibition within current drug development frameworks.

Conclusion & Outlook

PA-824, as provided by APExBIO, represents a foundational tool for advanced tuberculosis research, offering a well-characterized, high-purity bicyclic nitroimidazole derivative with robust, reproducible activity against drug-resistant M. tuberculosis. Its dual mechanism—NO-mediated respiratory inhibition and ketomycolate biosynthesis blockade—addresses both active and latent TB forms. Continued integration of PA-824 in combination regimens (e.g., with Q203 and ND-011992) is likely to accelerate development of more efficacious, resistance-suppressing therapies. For further details or to order the A1736 research kit, visit the PA-824 product page.